Tolerability and efficacy of single dose diethylcarbamazine (DEC) alone or co-administration with Ivermectin in the clearance of Wuchereria bancrofti microfilaraemia in Pondicherry, South India.
Identifieur interne : 008693 ( Main/Exploration ); précédent : 008692; suivant : 008694Tolerability and efficacy of single dose diethylcarbamazine (DEC) alone or co-administration with Ivermectin in the clearance of Wuchereria bancrofti microfilaraemia in Pondicherry, South India.
Auteurs : S P Pani ; G Subramanyam Reddy ; P. Vanamail ; N. Venkatesvarlou ; L K Das ; A P VijayanSource :
- The Journal of communicable diseases [ 0019-5138 ] ; 2004.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Animaux, Antiparasitaires (administration et posologie), Antiparasitaires (effets indésirables), Antiparasitaires (usage thérapeutique), Association de médicaments, Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (effets indésirables), Diéthylcarbamazine (usage thérapeutique), Femelle, Filaricides (administration et posologie), Filaricides (effets indésirables), Filaricides (usage thérapeutique), Filariose lymphatique (parasitologie), Filariose lymphatique (traitement médicamenteux), Humains, Inde, Ivermectine (administration et posologie), Ivermectine (effets indésirables), Ivermectine (usage thérapeutique), Microfilaria (), Mâle, Méthode en double aveugle, Parasitémie (parasitologie), Parasitémie (traitement médicamenteux), Résultat thérapeutique, Wuchereria bancrofti ().
- MESH :
- administration et posologie : Antiparasitaires, Diéthylcarbamazine, Filaricides, Ivermectine.
- effets indésirables : Antiparasitaires, Diéthylcarbamazine, Filaricides, Ivermectine.
- parasitologie : Filariose lymphatique, Parasitémie.
- traitement médicamenteux : Filariose lymphatique, Parasitémie.
- usage thérapeutique : Antiparasitaires, Diéthylcarbamazine, Filaricides, Ivermectine.
- Adolescent, Adulte, Animaux, Association de médicaments, Femelle, Humains, Inde, Microfilaria, Mâle, Méthode en double aveugle, Résultat thérapeutique, Wuchereria bancrofti.
English descriptors
- KwdEn :
- Adolescent, Adult, Animals, Antiparasitic Agents (administration & dosage), Antiparasitic Agents (adverse effects), Antiparasitic Agents (therapeutic use), Diethylcarbamazine (administration & dosage), Diethylcarbamazine (adverse effects), Diethylcarbamazine (therapeutic use), Double-Blind Method, Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (parasitology), Female, Filaricides (administration & dosage), Filaricides (adverse effects), Filaricides (therapeutic use), Humans, India, Ivermectin (administration & dosage), Ivermectin (adverse effects), Ivermectin (therapeutic use), Male, Microfilariae (drug effects), Parasitemia (drug therapy), Parasitemia (parasitology), Treatment Outcome, Wuchereria bancrofti (drug effects).
- MESH :
- chemical , administration & dosage : Antiparasitic Agents, Diethylcarbamazine, Filaricides, Ivermectin.
- chemical , adverse effects : Antiparasitic Agents, Diethylcarbamazine, Filaricides, Ivermectin.
- chemical , therapeutic use : Antiparasitic Agents, Diethylcarbamazine, Filaricides, Ivermectin.
- drug effects : Microfilariae, Wuchereria bancrofti.
- drug therapy : Elephantiasis, Filarial, Parasitemia.
- parasitology : Elephantiasis, Filarial, Parasitemia.
- Adolescent, Adult, Animals, Double-Blind Method, Drug Therapy, Combination, Female, Humans, India, Male, Treatment Outcome.
Abstract
The tolerability and efficacy of single dose DEC (12mg/kg body weight) or co-administration of DEC (6mg/kg body weight) with Ivermectin (200 or 400 mcg/kg of body weight) was studied in 60 asymptomatic W. bancrofti microfilariae (Mf) carriers following a double blind randomized design. The drugs were tolerated well. The incidence of adverse reactions of DEC (85.0%), DEC + Ivermectin 200mcg (95.0%) and DEC + Ivermectin 400mcg (100%) did not vary significantly (P>0.05). The mean score of adverse reaction intensity due to DEC + Ivermectin 200mcg (1.41) was significantly higher compared to DEC (0.61) (P<0.05). However, there was no significant difference between and DEC +Ivermectin 400mcg (0.89) and DEC + Ivermectin 200mcg (1.41) and DEC + Ivermectin 400mcg and DEC. The major adverse reactions were fever, headache and myalgia in all groups. The incidence and intensity of the adverse reactions were maximum between 24 to 48 hours of post therapy. The haematological and biochemical parameters did not vary significantly between pre and 7-day post therapy values in any of the study groups (P>0.05). Efficacy was measured in terms of proportion of cases clearing microfilaraemia completely and reduction in geometric mean parasite density in comparison to pre therapy levels. At the end of one year, DEC with Ivermectin 400mcg group showed significantly higher efficacy in complete clearance of Mf (94.4%) than that of DEC with Ivermectin 200mcg (60.0%) or DEC alone (52.6%) (P<0.05). However, no significant difference was observed in reduction of geometric mean Mf density (99.9%, 99.7%, 99.5% respectively). In all the groups, the tolerability and efficacy of the drugs were independent of host age and gender.
PubMed: 16506546
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003A71
- to stream PubMed, to step Curation: 003A71
- to stream PubMed, to step Checkpoint: 003A71
- to stream Ncbi, to step Merge: 002138
- to stream Ncbi, to step Curation: 002138
- to stream Ncbi, to step Checkpoint: 002138
- to stream Main, to step Merge: 008923
- to stream Main, to step Curation: 008693
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tolerability and efficacy of single dose diethylcarbamazine (DEC) alone or co-administration with Ivermectin in the clearance of Wuchereria bancrofti microfilaraemia in Pondicherry, South India.</title><author><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S P" last="Pani">S P Pani</name><affiliation><nlm:affiliation>Vector Control Research Centre (ICMR), Pondicherry.</nlm:affiliation><wicri:noCountry code="subField">Pondicherry</wicri:noCountry></affiliation></author><author><name sortKey="Reddy, G Subramanyam" sort="Reddy, G Subramanyam" uniqKey="Reddy G" first="G Subramanyam" last="Reddy">G Subramanyam Reddy</name></author><author><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P" last="Vanamail">P. Vanamail</name></author><author><name sortKey="Venkatesvarlou, N" sort="Venkatesvarlou, N" uniqKey="Venkatesvarlou N" first="N" last="Venkatesvarlou">N. Venkatesvarlou</name></author><author><name sortKey="Das, L K" sort="Das, L K" uniqKey="Das L" first="L K" last="Das">L K Das</name></author><author><name sortKey="Vijayan, A P" sort="Vijayan, A P" uniqKey="Vijayan A" first="A P" last="Vijayan">A P Vijayan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:16506546</idno><idno type="pmid">16506546</idno><idno type="wicri:Area/PubMed/Corpus">003A71</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003A71</idno><idno type="wicri:Area/PubMed/Curation">003A71</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003A71</idno><idno type="wicri:Area/PubMed/Checkpoint">003A71</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003A71</idno><idno type="wicri:Area/Ncbi/Merge">002138</idno><idno type="wicri:Area/Ncbi/Curation">002138</idno><idno type="wicri:Area/Ncbi/Checkpoint">002138</idno><idno type="wicri:doubleKey">0019-5138:2004:Pani S:tolerability:and:efficacy</idno><idno type="wicri:Area/Main/Merge">008923</idno><idno type="wicri:Area/Main/Curation">008693</idno><idno type="wicri:Area/Main/Exploration">008693</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tolerability and efficacy of single dose diethylcarbamazine (DEC) alone or co-administration with Ivermectin in the clearance of Wuchereria bancrofti microfilaraemia in Pondicherry, South India.</title><author><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S P" last="Pani">S P Pani</name><affiliation><nlm:affiliation>Vector Control Research Centre (ICMR), Pondicherry.</nlm:affiliation><wicri:noCountry code="subField">Pondicherry</wicri:noCountry></affiliation></author><author><name sortKey="Reddy, G Subramanyam" sort="Reddy, G Subramanyam" uniqKey="Reddy G" first="G Subramanyam" last="Reddy">G Subramanyam Reddy</name></author><author><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P" last="Vanamail">P. Vanamail</name></author><author><name sortKey="Venkatesvarlou, N" sort="Venkatesvarlou, N" uniqKey="Venkatesvarlou N" first="N" last="Venkatesvarlou">N. Venkatesvarlou</name></author><author><name sortKey="Das, L K" sort="Das, L K" uniqKey="Das L" first="L K" last="Das">L K Das</name></author><author><name sortKey="Vijayan, A P" sort="Vijayan, A P" uniqKey="Vijayan A" first="A P" last="Vijayan">A P Vijayan</name></author></analytic><series><title level="j">The Journal of communicable diseases</title><idno type="ISSN">0019-5138</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Antiparasitic Agents (administration & dosage)</term><term>Antiparasitic Agents (adverse effects)</term><term>Antiparasitic Agents (therapeutic use)</term><term>Diethylcarbamazine (administration & dosage)</term><term>Diethylcarbamazine (adverse effects)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (parasitology)</term><term>Female</term><term>Filaricides (administration & dosage)</term><term>Filaricides (adverse effects)</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>India</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (adverse effects)</term><term>Ivermectin (therapeutic use)</term><term>Male</term><term>Microfilariae (drug effects)</term><term>Parasitemia (drug therapy)</term><term>Parasitemia (parasitology)</term><term>Treatment Outcome</term><term>Wuchereria bancrofti (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Animaux</term><term>Antiparasitaires (administration et posologie)</term><term>Antiparasitaires (effets indésirables)</term><term>Antiparasitaires (usage thérapeutique)</term><term>Association de médicaments</term><term>Diéthylcarbamazine (administration et posologie)</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Femelle</term><term>Filaricides (administration et posologie)</term><term>Filaricides (effets indésirables)</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique (parasitologie)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Inde</term><term>Ivermectine (administration et posologie)</term><term>Ivermectine (effets indésirables)</term><term>Ivermectine (usage thérapeutique)</term><term>Microfilaria ()</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Parasitémie (parasitologie)</term><term>Parasitémie (traitement médicamenteux)</term><term>Résultat thérapeutique</term><term>Wuchereria bancrofti ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparasitic Agents</term><term>Diethylcarbamazine</term><term>Filaricides</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparasitic Agents</term><term>Diethylcarbamazine</term><term>Filaricides</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparasitic Agents</term><term>Diethylcarbamazine</term><term>Filaricides</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiparasitaires</term><term>Diéthylcarbamazine</term><term>Filaricides</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Microfilariae</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Parasitemia</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiparasitaires</term><term>Diéthylcarbamazine</term><term>Filaricides</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Parasitémie</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Parasitemia</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Parasitémie</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiparasitaires</term><term>Diéthylcarbamazine</term><term>Filaricides</term><term>Ivermectine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>India</term><term>Male</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Animaux</term><term>Association de médicaments</term><term>Femelle</term><term>Humains</term><term>Inde</term><term>Microfilaria</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Wuchereria bancrofti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The tolerability and efficacy of single dose DEC (12mg/kg body weight) or co-administration of DEC (6mg/kg body weight) with Ivermectin (200 or 400 mcg/kg of body weight) was studied in 60 asymptomatic W. bancrofti microfilariae (Mf) carriers following a double blind randomized design. The drugs were tolerated well. The incidence of adverse reactions of DEC (85.0%), DEC + Ivermectin 200mcg (95.0%) and DEC + Ivermectin 400mcg (100%) did not vary significantly (P>0.05). The mean score of adverse reaction intensity due to DEC + Ivermectin 200mcg (1.41) was significantly higher compared to DEC (0.61) (P<0.05). However, there was no significant difference between and DEC +Ivermectin 400mcg (0.89) and DEC + Ivermectin 200mcg (1.41) and DEC + Ivermectin 400mcg and DEC. The major adverse reactions were fever, headache and myalgia in all groups. The incidence and intensity of the adverse reactions were maximum between 24 to 48 hours of post therapy. The haematological and biochemical parameters did not vary significantly between pre and 7-day post therapy values in any of the study groups (P>0.05). Efficacy was measured in terms of proportion of cases clearing microfilaraemia completely and reduction in geometric mean parasite density in comparison to pre therapy levels. At the end of one year, DEC with Ivermectin 400mcg group showed significantly higher efficacy in complete clearance of Mf (94.4%) than that of DEC with Ivermectin 200mcg (60.0%) or DEC alone (52.6%) (P<0.05). However, no significant difference was observed in reduction of geometric mean Mf density (99.9%, 99.7%, 99.5% respectively). In all the groups, the tolerability and efficacy of the drugs were independent of host age and gender.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Das, L K" sort="Das, L K" uniqKey="Das L" first="L K" last="Das">L K Das</name><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S P" last="Pani">S P Pani</name><name sortKey="Reddy, G Subramanyam" sort="Reddy, G Subramanyam" uniqKey="Reddy G" first="G Subramanyam" last="Reddy">G Subramanyam Reddy</name><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P" last="Vanamail">P. Vanamail</name><name sortKey="Venkatesvarlou, N" sort="Venkatesvarlou, N" uniqKey="Venkatesvarlou N" first="N" last="Venkatesvarlou">N. Venkatesvarlou</name><name sortKey="Vijayan, A P" sort="Vijayan, A P" uniqKey="Vijayan A" first="A P" last="Vijayan">A P Vijayan</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008693 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008693 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16506546
|texte= Tolerability and efficacy of single dose diethylcarbamazine (DEC) alone or co-administration with Ivermectin in the clearance of Wuchereria bancrofti microfilaraemia in Pondicherry, South India.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16506546" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |